Shiga toxin-producing Escherichia coli infections in children

Česká verzia

Authors: L. Karnišová ¹; F. Fencl ¹; M. Marejková ²; M. Malina ¹; J. Zieg ¹; K. Bláhová ¹
Authors place of work: Pediatrická klinika 2. LF UK a FN Motol, Praha přednosta prof. MUDr. J. Lebl, CSc. ¹; Národní referenční laboratoř pro E. coli a shigely, Státní zdravotní ústav, Praha vedoucí ing. M. Marejková, Ph. D. ²
Published in the journal: Čes-slov Pediat 2016; 71 (2): 98-103.
Category: Přehledový článek

Summary

Shiga toxin-producing Escherichia coli (STEC) are an important cause of diarrhea and the major cause of typical form of hemolytic-uremic syndrome (HUS) worldwide. Manifestation of STEC infection can be diverse, from uncomplicated diarrhea through hemorrhagic colitis, to a serious systemic disease – HUS, that is the most common cause of acute kidney injury, especially in young children.

Due to possible progression of diarrhea to life-threatening illness, all physicians treating patients with diarrhea should get familiar with the epidemiology, pathogenesis and clinical symptomes of infection caused by the organism.

This article describes the history, epidemiology, pathogenesis, clinical aspects, and diagnostic methods of STEC infections.

Key words:
Shiga toxin-producing E. coli (STEC), hemolytic-uremic syndrome (HUS), STEC-HUS/typical HUS/classical form of HUS/diarrhea positive HUS/D+HUS, diagnosis, epidemiology, clinical symptoms

Zdroje

1. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365 (9464): 1073–1086.

2. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290: 1360–1370.

3. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1: 619–620.

4. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308: 681–685.

5. O’Brien AO, Lively TA, Chen ME, et al. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet 1983; 1: 702.

6. Scheutz F, Teel LD, Beutin L, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012; 50 (9): 2951–2963.

7. Bielaszewska M, Mellmann A, Bletz S, et al. Entero-hemorrhagic Escherichia coli O26:H11/H: a new virulent clone emerges in Europe. Clin Infect Dis 2013; 56: 1373–1381.

8. Mellmann A, Bielaszewska M, Köck R, et al. Analysis of collection of hemolytic uremic syndrome-associated enterohemorrhagic Escherichia coli. Emerg Infect Dis 2008; 14 (8): 1287–1290.

9. Luna-Gierke RE, Griffin PM, Gould LH, et al. Outbreaks of non-O157 Shiga toxin-producing Escherichia coli infection: USA. Epidemiol Infect 2014; Jan 7: 1–11.

10. Käppeli U, Hächler H, Giezendanner N, et al. Human infections with non-O157 Shiga toxin-producing Escherichia coli, Switzerland, 2000–2009. Emerg Infect Dis 2011; 17 (2): 180–185.

11. Marejková M, Bláhová K, Janda J, et al. Enterohemorrhagic Escherichia coli as causes of Hemolytic Uremic Syndrome in the Czech Republic. PLoS ONE 2013; 8 (9): e73927. doi:10.1371/journal.pone 0073927.

12. Bláhová K, Fencl F. Kazuistiky z pediatrie. 1. vyd. Praha: Mladá fronta, 2014: 1–197. Aeskulap. ISBN 978-80-204-3392-3.

13. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11 (9): 671–676.

14. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365 (19): 1771–1780.

15. Bielaszewská M, Janda J. Microbiological aspects of infection with verotoxin-producing E.coli strains in children with the hemolytic-uremic syndrome. Cesk Epidemiol Mikrobiol Imunol 1989 Jul; 38 (4): 237–244.

16. Srámková L, Bielaszewská M, Janda J, et al. Vero cytotoxin-producing strains of Escherichia coli in children with haemolytic uraemic syndrome and diarrhoea in Czechoslovakia. Infection 1990 Jul-Aug; 18 (4): 204–209.

17. Bielaszewska M, Janda J, Blahová K, et al. Verocytotoxin-producing Escherichia coli in children with hemolytic uremic syndrome in the Czech Republic. Clin Nephrol 1996 Jul; 46 (1): 42–44.

18. Bielaszewska M, Janda J, Bláhová K, et al. Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat‘s milk. Epidemiol Infect 1997 Dec; 119 (3): 299–305.

19. Marejková M, Petráš P. Enterohemoragické Escherichia coli jako původci průjmu v České republice, 1965–2013. Epidemiol Mikrobiol Imunol 2014; 63 (3): 173–183.

20. Alexa P, Konstantinova L, Zajacova-Sramkova Z. Faecal shedding of verotoxigenic Escherichia coli in cattle in the Czech Republic. Veterinární Medicina 2011; 56 (4): 149–155.

21. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295 (6–7): 405–418.

22. Koláčková I, Házová K, Skočková A, et al. Výskyt shigatoxigenních kmenů Escherichia coli u prasat a skotu na jatkách v ČR v roce 2013. Klin Mikrobiol Infect Lek 2014; 20 (2): 36–39.

23. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost 2005 Aug; 94 (2): 312–318.

24. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H:evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182 (10): 6394–6400.

25. Ehrlenbach S, Rosales A, Posch W, et.al. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 2013; 81 (8): 2678–2685.

26. Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010; 2 (12): 2769–2794.

27. Bláhová K. Hemolyticko-uremický syndrom. Vnitř Lék 2004; 50: 519–525.

28. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16 (4): 1035.

29. Milford D. The hemolytic uremic syndromes in the United Kingdom. In: Kaplan BS, Trompeter RS, Koale JL (eds). Hemolytic Uremic syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker, 1992: 39–59.

30. Zieg J, Blahova K, Dusek J, et al. Hemolyticko-uremicky syndrom. Pediatr praxi 2011; 12 (2): 102–104.

31. Bielaszewska M, Köck R, Friedrich AW, et al. Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm? PLoS One 2007 Oct 10; 2 (10): e1024.

32. Liptáková A, Siegfried L, Podracká Ľ, et al. Detection of Shiga toxins, intimin and enterohaemolysin in Escherichia coli strains isolated from children in eastern Slovakia. Folia Microbiol (Praha) 2002; 47 (2): 185–189.